

STAAR SURGICAL CO
Form SC 13D/A
September 30, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D/A
THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 16)

STAAR Surgical Company
(Name of Issuer)

Common Stock
(Title of Class of Securities)

852312305
(CUSIP Number)

Neal C. Bradsher
c/o Broadwood Capital, Inc.
724 Fifth Avenue, 9th Floor
New York, New York 10019
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)

September 29, 2015
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13D-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [].

CUSIP
852312305
No.

NAME OF
1. REPORTING
PERSONS
Broadwood
Partners, L.P.

CHECK THE
APPROPRIATE
2. BOX IF A
MEMBER OF A
GROUP

(a)
 (b)

3. SEC USE
ONLY

4. SOURCE OF
FUNDS

WC

CHECK BOX
IF
DISCLOSURE
OF LEGAL
PROCEEDINGS
5. IS
REQUIRED
PURSUANT
TO ITEMS
2(d) OR 2(e)

CITIZENSHIP
OR PLACE
6. OF
ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH

SOLE
7. VOTING
POWER

0

SHARED
8. VOTING
POWER

8,617,562

SOLE
9. DISPOSITIVE
POWER

0

SHARED
10. DISPOSITIVE
POWER

8,617,562

AGGREGATE
AMOUNT
BENEFICIALLY
11. OWNED BY
EACH
REPORTING
PERSON

8,617,562

CHECK BOX
IF THE
AGGREGATE
12. AMOUNT IN
ROW (11)
EXCLUDES
CERTAIN
SHARES

PERCENT OF
CLASS
13. REPRESENTED
BY AMOUNT
IN ROW (11)

21.6%

TYPE OF
14. REPORTING
PERSON

PN

CUSIP
852312305
No.

1. NAME OF
REPORTING
PERSONS

Broadwood
Capital, Inc.

2. CHECK THE
APPROPRIATE
BOX IF A
MEMBER OF A
GROUP

(a)
 (b)

3. SEC USE
ONLY

4. SOURCE OF
FUNDS

AF

5. CHECK BOX
IF
DISCLOSURE
OF LEGAL
PROCEEDINGS
IS
REQUIRED
PURSUANT
TO ITEMS
2(d) OR 2(e)

6. CITIZENSHIP
OR PLACE
OF
ORGANIZATION

New York

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH

REPORTING
PERSON WITH

SOLE
7. VOTING
POWER

0

SHARED
8. VOTING
POWER

8,617,562

SOLE
9. DISPOSITIVE
POWER

0

SHARED
10. DISPOSITIVE
POWER

8,617,562

AGGREGATE
AMOUNT
11. BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON

8,617,562

CHECK BOX
IF THE
12. AGGREGATE
AMOUNT IN
ROW (11)
EXCLUDES
CERTAIN
SHARES

13. PERCENT OF
CLASS
REPRESENTED
BY AMOUNT

IN ROW (11)

21.6%

TYPE OF
14. REPORTING
PERSON

CO, IA

CUSIP
852312305
No.

1. NAME OF
REPORTING
PERSONS

Neal C.
Bradsher

2. CHECK THE
APPROPRIATE
BOX IF A
MEMBER OF A
GROUP

(a)
 (b)

3. SEC USE
ONLY

4. SOURCE OF
FUNDS

WC, AF, OO

5. CHECK BOX
IF
DISCLOSURE
OF LEGAL
PROCEEDINGS
IS
REQUIRED
PURSUANT
TO ITEMS
2(d) OR 2(e)

6. CITIZENSHIP
OR PLACE
OF
ORGANIZATION

United States
of America

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH

REPORTING
PERSON WITH

SOLE
7. VOTING
POWER

25,900

SHARED
8. VOTING
POWER

8,617,562

SOLE
9. DISPOSITIVE
POWER

25,900

SHARED
10. DISPOSITIVE
POWER

8,617,562

AGGREGATE
AMOUNT
11. BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON

8,643,462

CHECK BOX
IF THE
12. AGGREGATE
AMOUNT IN
ROW (11)
EXCLUDES
CERTAIN
SHARES

13. PERCENT OF
CLASS
REPRESENTED

BY AMOUNT
IN ROW (11)

21.7%

TYPE OF
14. REPORTING
PERSON

IN

CUSIP No. 852312305

Item 1. Security and Issuer.

STAAR
Surgical
Company,
Common
Stock, par
value \$0.01
per share (the
"Shares")

STAAR
Surgical
Company
1911
Walker
Avenue
Monrovia,
California
91016

Item 2. Identity and Background.

NO
MATERIAL
CHANGE
FROM THE
SCHEDULE
13D/A FILED
ON JUNE 28,
2010.

Item 3. Source and Amount of Funds or Other Consideration.

As of the date
hereof
Broadwood
Partners may
be deemed to
beneficially
own 8,617,562

Shares.

As of the date
hereof
Broadwood
Capital may be
deemed to
beneficially
own 8,617,562
Shares.

As of the date
hereof Neal C.
Bradsher may
be deemed to
beneficially
own 8,643,462
Shares.

No borrowed
funds were
used to
purchase the
Shares, other
than any
borrowed
funds used for
working
capital
purposes in the
ordinary
course of
business.

Item
4. Purpose of Transaction.

The Reporting Persons acquired their Shares of the Issuer for investment purposes.

The Reporting Persons have no plans or proposals which, other than as expressly set forth below, would relate to or would result in: (a) the acquisition of additional securities of the Issuer or the disposition of presently-owned securities of the Issuer; (b) any extraordinary corporate transaction involving the Issuer; (c) a sale or transfer of a material amount of assets of the Issuer; (d) any change in the present Board of Directors or management of the Issuer; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any material change in the operating policies or corporate structure of the Issuer; (g) any change in the Issuer's charter or by-laws; (h) the Shares of the Issuer ceasing to be authorized to be quoted in the over-the-counter security markets; or (i) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes or transactions in the number of shares they may be deemed to beneficially own.

The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to improve shareholder value.

The Reporting Persons are encouraged by the recent changes to the Issuer's management team, which they believe have improved the odds that the Issuer may successfully overcome its recent setbacks and realize its substantial long-term growth opportunity. In light of the recent management changes, and consistent with the Reporting Persons' longstanding belief in the Issuer's proprietary technology and substantial growth opportunity, the Reporting Persons recently increased their ownership of the Issuer's shares.

However, the Reporting Persons remain concerned that while the Issuer's management team has improved, its Board of Directors' alignment with and representation of the Issuer's shareholders are still inadequate. The results of the Issuer's shareholders' votes at the Issuer's most recent annual meeting made clear that shareholders do not support certain members of the current Board. The Reporting Persons are encouraged that there have been two subsequent improvements to the Board, including the appointment of Mr. Wall. However, these changes represent only slow and limited progress toward a board that is aligned with and represents the Issuer's shareholders. The Reporting Persons intend to remain in dialogue with members of the Board and other shareholders about potential further improvements to the Board and the Issuer's corporate governance.

Item 5. Interest in Securities of the Issuer.

As of the date hereof, Broadwood Partners may be deemed to be the beneficial owner of 8,617,562 Shares, (a, b) constituting 21.6% of the Shares of the Issuer, based upon the 39,804,516 Shares deemed outstanding as of July 24, 2015.

Broadwood Partners has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 8,617,562 Shares; has sole power to dispose or direct the disposition of 0 Shares; and has shared power to dispose or direct the disposition of 8,617,562 Shares.

As of the date hereof, Broadwood Capital may be deemed to be the beneficial owner of 8,617,562 Shares, constituting 21.6% of the Shares of the Issuer, based upon the 39,804,516 Shares deemed outstanding as of July 24, 2015.

(a, Broadwood Capital has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or b) direct the vote of 8,617,562 Shares; has sole power to dispose or direct the disposition of 0 Shares; and has shared power to dispose or direct the disposition of 8,617,562 Shares.

Broadwood Capital specifically disclaims beneficial ownership in the Shares reported herein except to the extent of its pecuniary interest therein.

As of the date hereof, Neal C. Bradsher may be deemed to be the beneficial owner of 8,643,462 Shares, constituting 21.7% of the Shares of the Issuer, based upon the 39,804,516 Shares deemed outstanding as of July 24, 2015.

(a, Neal C. Bradsher has the sole power to vote or direct the vote of 25,900 Shares; has the shared power to vote or b) direct the vote of 8,617,562 Shares; has sole power to dispose or direct the disposition of 25,900 Shares; and has shared power to dispose or direct the disposition of 8,617,562 Shares.

Neal C. Bradsher specifically disclaims beneficial ownership in the Shares reported herein except to the extent of his pecuniary interest therein.

The trading dates, number of Shares purchased and sold and price per share for all transactions in the Shares by (c) the Reporting Persons in the past 60 days are set forth in Exhibit B and all such transactions were effected in open market transactions.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

N/A

Item 7. Material to be Filed as Exhibits.

Exhibit A: Joint Filing Agreement.

Exhibit B: Transactions by the Reporting Persons during the past 60 Days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BROADWOOD PARTNERS,
L.P.

By: Broadwood Capital, Inc.

By: /s/ Neal C. Bradsher

Name: Neal C. Bradsher

Title: President

BROADWOOD CAPITAL,
INC.*

By: /s/ Neal C. Bradsher

Name: Neal C. Bradsher

Title: President

/s/ Neal C. Bradsher
NEAL C. BRADSHER *

September 29, 2015

* The Reporting Persons disclaim beneficial ownership over the securities reported herein except to the extent of the reporting persons' pecuniary interest therein.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit A

Joint Filing Agreement

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of STAAR Surgical Company.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Executed this 29th day of September, 2015.

BROADWOOD PARTNERS,

L.P.

By: Broadwood Capital, Inc.

By: /s/ Neal C. Bradsher

Name: Neal C. Bradsher

Title: President

BROADWOOD CAPITAL,

INC.

By: /s/ Neal C. Bradsher

Name: Neal C. Bradsher

Title: President

/s/ Neal C. Bradsher

NEAL C. BRADSHER

Exhibit B

Transactions by the Reporting Persons during the past 60 Days

TRANSACTIONS IN THE SHARES

| Date of | Number of Shares | |
|--------------------|------------------------|------------------------|
| <u>Transaction</u> | <u>Purchase/(Sold)</u> | <u>Price of Shares</u> |
| 8/21/2015 | 50,800 | \$7.0669 ¹ |
| 8/24/2015 | 122,577 | \$7.2037 ² |
| 8/25/2015 | 15,504 | \$7.2391 ³ |
| 9/25/2015 | 141,651 | \$7.074 ⁴ |
| 9/28/2015 | 110,724 | \$7.0725 ⁵ |
| 9/29/2015 | 58,724 | \$7.1285 ⁶ |

¹ This constitutes the weighted average purchase price. The prices range from \$6.91 to \$7.24. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

² This constitutes the weighted average purchase price. The prices range from \$7.09 to \$7.24. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

³ This constitutes the weighted average purchase price. The prices range from \$7.20 to \$7.24. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁴ This constitutes the weighted average purchase price. The prices range from \$6.865 to \$7.14. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁵ This constitutes the weighted average purchase price. The prices range from \$6.97 to \$7.14. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

⁶ This constitutes the weighted average purchase price. The prices range from \$7.00 to \$7.14. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.